CHMP backs Joenja for APDS, putting EU approval in sight
Pharming has cleared an important European regulatory hurdle for Joenja, its oral PI3Kδ inhibitor leniolisib, after the EMA’s CHMP adopted a positive opinion recommending approval for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients ages 12 and older. The March 27, 2026, opinion puts the drug on track for a final European Commission decision in the second quarter of 2026 and, if cleared, would make Joenja the first approved APDS treatment in the European Union. (stocktitan.net)
The decision builds on a regulatory story that has been moving in stages across major markets. The FDA first approved Joenja in March 2023 for APDS in adults and children 12 and older, making it the first approved therapy for the disease in the U.S. The U.K. later authorized the drug for the same age group, and Japan approved it on March 24, 2026, with a broader label that includes children ages 4 to 11. That broader Japanese approval came just weeks after Pharming disclosed that the FDA had issued a Complete Response Letter to its U.S. supplemental application for the younger pediatric group. (pharming.com)
Clinically, the CHMP opinion appears to rest on the same core evidence package that supported prior approvals. In the pivotal phase 3 trial, 31 patients ages 12 and older were randomized 2:1 to leniolisib 70 mg twice daily or placebo for 12 weeks, with statistically significant improvements in co-primary markers tied to lymphoproliferation and immune dysregulation. Longer-term open-label data have followed 37 patients, with Pharming citing a median treatment duration of roughly three years. More recent published research has also tried to extend the picture beyond biomarkers, including a 2026 Frontiers in Immunology paper that assessed qualitative reports from 36 leniolisib-treated individuals and described perceived improvements in APDS-related symptoms and health-related quality of life. (pubmed.ncbi.nlm.nih.gov)
APDS remains an ultra-rare inborn error of immunity, and that rarity shapes both the evidence base and the commercial strategy. Patient advocacy and educational groups have described the syndrome as a disorder marked by recurrent respiratory infections, lymphoproliferation, immune dysregulation, and risk of long-term complications including bronchiectasis and lymphoma. Before leniolisib, management typically relied on supportive or symptom-directed care, including antibiotics, immunoglobulin replacement, immunosuppressive therapy, and, in selected cases, hematopoietic stem cell transplant. That backdrop helps explain why regulators have been willing to act on relatively small datasets when the mechanistic rationale is strong and the unmet need is clear. (primaryimmune.org)
Direct outside expert reaction to this week’s CHMP opinion was limited in publicly available sources, but the broader specialist literature has been consistently supportive of leniolisib as a targeted treatment approach. Investigators in Blood and later follow-up publications have framed the drug as a disease-specific therapy aimed at the root PI3Kδ pathway abnormality rather than just downstream symptom control. That said, the recent FDA setback in younger children is a useful counterweight to the positive narrative, suggesting that regulators are still scrutinizing the full package closely, especially when sponsors seek to broaden age ranges or manufacturing readiness across regions. (ashpublications.org)
Why it matters: For veterinary professionals following biopharma and translational medicine, this isn’t an animal health story, but it is a useful case study in how rare-disease therapeutics now move through the global system. Joenja’s path shows how a highly targeted therapy can win traction market by market, how tiny pivotal trials can still support approvals in orphan diseases, and how post-approval expansion into younger populations may prove more difficult than the first approval itself. It also reflects a broader industry trend: regulators and companies are increasingly leaning on mechanistic precision, extension studies, and real-world evidence to build confidence where large trials are unrealistic. (stocktitan.net)
For clinicians, the practical lesson is less about APDS specifically and more about the growing regulatory acceptance of narrow, biomarker-driven immune therapies. That matters because the same development logic is increasingly shaping pipelines across immunology, oncology, and, by extension, comparative and translational research that can influence veterinary drug development strategies as well. Pharming has already moved leniolisib into additional primary immunodeficiency settings with immune dysregulation, signaling that the company sees APDS as a beachhead rather than the endpoint. (pharming.com)
What to watch: The immediate next milestone is the European Commission’s final decision, which typically comes within about two months of a positive CHMP opinion; after that, attention will likely shift to EU launch timing, reimbursement uptake, and whether Pharming can resolve the U.S. pediatric regulatory issues for children ages 4 to 11. (health.ec.europa.eu)